NCT06917079phase 1recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

ClinicalTrials.gov

665

Enrollment · estimated

Countries · 17 sites

2027-08

Primary completion

3 mo ago

Record updated

Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required

Biomarker requirement language

Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
55/100
Opportunity
New phase 1 trial NCT06917079 posted by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics): "BBO-11818 in Adult Subjects With KRAS Mutant Cancer".
ClinicalTrials.gov record updated 98 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
* Measurable disease by RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
* Life expectancy \>24 weeks
* Adequate organ function

Exclusion Criteria:

* Malignancy within the last 2 years as specified in the protocol
* Untreated brain metastases

Other inclusion/exclusion criteria are specified in the protocol.